InMed Pharmaceuticals EBITDA 2011-2025 | INM

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA InMed Pharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-7.75 M	-18.4 M	-10.1 M	-11.9 M	-13.5 M	-8.49 M	-4.38 M	-2.29 M	-4.2 M	-1.23 M	-49.2 K	-171 K	-244 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-49.2 K	-18.4 M	-6.36 M

Quarterly EBITDA InMed Pharmaceuticals

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-1.95 M	-2.05 M	-3.46 M	-5.51 M	-3.42 M	-4.23 M	-2.94 M	-7.18 M	-3.07 M	-2.21 M	28 K	64.8 K	28 K	28.2 K	30.2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
64.8 K	-7.18 M	-2.39 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Graybug Vision GRAY	-38 M	$ 0.44	-11.23 %	$ 9.65 M	USA
AgeX Therapeutics AGE	-9.76 M	$ 11.3	-10.17 %	$ 12.2 K	-
Galera Therapeutics GRTX	-20.1 M	$ 0.14	-32.59 %	$ 7.61 M	USA
AnPac Bio-Medical Science Co., Ltd. ANPC	-100 M	$ 4.37	-1.58 %	$ 28.1 M	China
Axon Enterprise AXON	107 M	$ 723.51	-1.19 %	$ 54.8 B	USA
Caladrius Biosciences CLBS	-22.2 M	$ 0.43	-16.75 %	$ 25.8 M	USA
Sorrento Therapeutics SRNE	-389 M	$ 0.27	-29.58 %	$ 126 M	USA
BeiGene, Ltd. BGNE	-396 M	$ 184.71	0.49 %	$ 251 B	Cayman-islands
Heron Therapeutics HRTX	-9.04 M	$ 1.2	3.02 %	$ 183 M	USA
ContraFect Corporation CFRX	-64.5 M	$ 1.47	-5.16 %	$ 5.39 M	USA
Orchard Therapeutics plc ORTX	-124 M	$ 4.93	1.02 %	$ 90.8 M	Britain
Midatech Pharma plc MTP	-7 M	$ 0.29	-18.52 %	$ 27.3 M	Britain
Advaxis ADXS	-35.9 M	$ 0.31	-9.65 %	$ 45.9 M	USA
Heat Biologics, Inc. HTBX	-24.7 M	$ 3.93	-5.76 %	$ 99.8 M	USA
La Jolla Pharmaceutical Company LJPC	21.9 M	$ 6.2	-	$ 154 M	USA
Zymeworks ZYME	-212 M	$ 6.42	-	$ 404 M	Canada
Aeterna Zentaris AEZS	-8.67 M	$ 5.72	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	-61.4 M	$ 10.5	-	$ 231 M	USA
Kadmon Holdings, Inc. KDMN	-101 M	$ 9.5	-	$ 1.7 B	USA
BioDelivery Sciences International BDSI	37.3 M	$ 2.58	-4.8 %	$ 255 M	USA
Zosano Pharma Corporation ZSAN	-29.8 M	$ 0.56	7.23 %	$ 2.72 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	$ 0.5	-	$ 7.46 M	Israel
Kiromic BioPharma KRBP	-21.5 M	$ 3.15	6.61 %	$ 3.08 M	USA
Acceleron Pharma Inc. XLRN	-133 M	$ 179.68	-	$ 10.9 B	USA
Albireo Pharma ALBO	-123 M	$ 44.15	-0.23 %	$ 916 M	USA
Stealth BioTherapeutics Corp MITO	-46.2 M	$ 0.32	-	$ 23.9 M	USA
Trillium Therapeutics Inc. TRIL	-60.9 M	$ 18.44	-	$ 1.94 B	Canada
Kaleido Biosciences KLDO	-85.3 M	$ 0.29	-3.69 %	$ 12.4 M	USA
Entasis Therapeutics Holdings ETTX	-52.2 M	$ 2.19	-	$ 105 M	USA
Humanigen HGEN	-68.3 M	$ 0.04	-81.12 %	$ 4.28 M	USA
Aptinyx APTX	-62.4 M	$ 0.06	-39.0 %	$ 4.57 M	USA
Tyme Technologies TYME	-27.2 M	$ 0.31	8.07 %	$ 54 M	USA
Forward Pharma A/S FWP	-3.87 M	$ 2.64	-0.75 %	$ 18.7 M	Danmark
Applied Genetic Technologies Corporation AGTC	-16.2 M	$ 0.39	-	$ 26.5 M	USA
Celyad Oncology SA CYAD	-26.4 M	$ 0.47	-	$ 12.5 M	Belgium
Brickell Biotech BBI	-6.32 M	$ 2.11	-5.38 %	$ 6.06 M	USA
Genocea Biosciences GNCA	-50.5 M	$ 0.05	-15.0 %	$ 3.04 M	USA
Codiak BioSciences CDAK	-64.2 M	$ 0.06	-55.98 %	$ 2.15 M	USA
Concert Pharmaceuticals CNCE	-76 M	$ 8.37	-	$ 401 M	USA
AIkido Pharma AIKI	-11.4 M	$ 3.17	1.93 %	$ 17.4 M	USA
Novo Nordisk A/S NVO	64.7 B	$ 49.14	-0.62 %	$ 421 B	Danmark
Calithera Biosciences CALA	-115 M	$ 0.37	-10.95 %	$ 876 K	USA
Forma Therapeutics Holdings FMTX	-172 M	$ 20.01	-	$ 958 M	USA
Oncolytics Biotech ONCY	-26.2 M	$ 1.09	-8.58 %	$ 115 M	Canada
Arena Pharmaceuticals ARNA	-620 M	$ 49.55	-6.81 %	$ 3.04 B	USA
ORIC Pharmaceuticals ORIC	-142 M	$ 12.52	-4.86 %	$ 873 M	USA
Sierra Oncology SRRA	-94.3 M	$ 54.89	-0.05 %	$ 1.34 B	Canada
Regulus Therapeutics RGLS	-30.9 M	$ 8.16	-	$ 155 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Precigen PGEN	6.67 M	$ 4.17	0.72 %	$ 1.02 B	USA